U.S. Solid Tumor Testing Market: Focus on Technology, Cancer Type, Type of Biomarker, By Application, by End User, and Region - Analysis and Forecast, 2022-2032

Report
283 Pages
June 2022
Region: United States
BIS Research
ID: 5067401

U.S. Solid Tumor Testing Market Industry Overview

The U.S. solid tumor testing market was estimated to be at $9,498.8 million in 2021, which is expected to grow with a CAGR of 6.19% during the forecast period 2022-2032 and reach $18,287.6 million by 2032. The growth in the U.S. solid tumor testing market is expected to be driven by increasing awareness of early tumor diagnosis and tests along with the increasing geriatric population. Furthermore, increasing cancer incidences in the pediatric population.

Market Lifecycle Stage

The U.S. solid tumor testing market is progressing rapidly. Significant increases in the research and development activities pertaining to solid tumor testing are underway to develop better testing kits and assays, which are expected to increase due to the rising frequency and efficiency of cancer testing products. The recent allocation of $6.44 billion to NCI in FY2019, as per the Department of Health and Human Services Appropriations Act and the 21st Century Cures Act, has further brightened the prospects for key players to bring a diagnostic or therapeutic innovation to the market with conditional support (pertaining to innovation or diagnostic/therapeutic breakthrough and a relative grant triggered from NCI).

Impact

The presence of major service providers of solid tumor testing in the U.S. has a major impact on the market. For instance, Illumina, Inc. acquired GRAIL which is a cancer detection healthcare company. With this acquisition, Illumina, Inc. can accelerate the adoption of this lifesaving Galleri blood test worldwide which is known to detect 50 different cancer types.
Companies such as QIAGEN partnered with PGDx for molecular cancer testing. With the help of this, laboratories will be able to receive standardized reporting from QIAGEN and receive access to QIAGEN’s QCI Interpret One for rapid next-generation sequencing tests.

Impact of COVID-19

It is known that people with cancer are more susceptible to infectious agents due to their impaired immune systems. However, this was found inconsistent with COVID-19. The very early studies found that people with cancer are more susceptible to COVID-19 and its severe complications, especially for patients with lung or hematological cancers. However, some of the most recent, larger studies found no increased risk of death due to cancer type or timing of cancer treatment.

There were numerous consequences due to the COVID-19 pandemic, especially because of the reduced access to care for other illnesses. As the number of individuals becoming ill from COVID-19 kept increasing and for the protection of healthy individuals from being affected by the disease, all non-urgent healthcare facilities were suspended in the U.S. by the recommendation of the American Cancer Society and other organizations. Even though these measures were necessary, they led to delays in cancer diagnosis, screening, and treatment. This led to increased later-stage cancer diagnoses and, in turn, cancer deaths that may have been preventable.

Market Segmentation

By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence In-Situ Hybridization, Immunohistochemistry, Liquid Chromatography/Mass Spectrometry, Other Technologies)

Based on technology, the U.S. solid tumor testing market is expected to be dominated by the next-generation sequencing technology. This is due to the high accuracy and efficiency of next-generation sequencing techniques.

By Cancer Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Endometrial Cancer, Lymphoma, Thyroid Cancer, Brain Cancer, Other Cancer Types)

Based on cancer type, the U.S. solid tumor testing market is dominated by breast cancer, owing to an increasing number of patients suffering from breast cancer and also more awareness and better diagnosis of cancer.

By Type of Biomarker (Genetic Biomarker, Protein Biomarker)

The genetic biomarkers segment dominates the U.S. solid tumor testing market; however, the protein biomarkers segment shows the largest CAGR of 6.61%. The growth in this segment is mainly due to the growth in research and development, which is leading to the discovery of more biomarkers.

By Application (Clinical, Research)

The clinical application dominated the application segment. This is because the solid tumor testing market is already well established with many clinical applications. However, the research segment has a higher CAGR of 6.61% as compared to 5.92% for clinical and is expected to grow at a fast pace during the forecast period. Research has increased due to the emergence of personalized medicine.

By End User (Hospitals, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutions, Other End Users)

Hospitals dominated the end-user segment. This is due to an increasing number of oncologists playing a key role in the recommendation and data interpretation of solid tumor tests. Due to this, most tests are performed through the hospitals, thereby making it a dominating segment of the market and its growth.

By Region (The Southern U.S., The Midwest U.S., The Mid-Atlantic U.S., The West U.S., The Southwest U.S., New England)

The Southern U.S. dominated the regions with a revenue of $2,614.7 in 2021. The high incidence of cancer in a few states like California, Florida, and Texas are the key areas for solid tumor testing market growth.

Recent Developments in U.S. Solid Tumor Testing Market

In December 2021, Opko Health, Inc. secured FDA approval for its 4Kscore test that is approved for men 45 years or older who haven’t had a prior prostate biopsy or are biopsy negative.
In April 2021, NeoGenomics Laboratories launched biomarker assist KRAS single gene test. This test is used for advanced or metastatic small cell lung cancer patients.
In November 2020, NeoGenomics Laboratories. started mobile phlebotomy services for liquid biopsy tests. These tests include InVisionFirst-Lung, which is a non-small cell lung liquid biopsy test, and the NeoLab liquid biopsy test, which is used for all solid tumors and hematological cancers.
In February 2020, QIAGEN obtained a CE mark for its therascreen PIK3CA mutation assay. This test can be used to identify breast cancer.

Demand - Drivers and Limitations

Following are the demand drivers for the U.S. solid tumor testing market

Rising Advancements in Solid Tumor Testing and Rapid Usage of Liquid Biopsy
Early Cancer Detection with Multi-Cancer Tests
Increasing Adoption of Inorganic Growth Strategies in the Market
Spike Increase in the Research Funding from National Cancer Institute
Rapid Adoption of Genetic Testing

The market is expected to face some limitations too due to the following challenges:

Reimbursement Cuts in the U.S.
High Pricing Pressure

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The report considers both the product-based and the service-based companies. Since tumor testing is a service, most of the companies considered are service based. However, technologies such as NGS, PCR, and IHC, that are involved in the testing process of solid tumors are also discussed in detail.

Growth/Marketing Strategy: The key components in solid tumor testing consist of kits and assays, generally purchased by the testing companies and the testing services themselves. The entire workflow is well explained in the report, along with pricing analysis taking into account the main technologies that are used in testing.

Competitive Strategy: Key players in the U.S. solid tumor testing market were analyzed and profiled in the study, consisting of both product-based and service-based companies as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the U.S. solid tumor testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top segment players leading the market include solid tumor testing service givers that capture around 70% of the presence in the market, and solid tumor testing product manufacturers contribute around 30% of the presence in the market as of 2021

Some of the prominent names established in this market are:

Abbott.
ARUP Laboratories
Bio-Rad Laboratories, Inc.
Caris Life Sciences.
F. Hoffmann-La Roche Ltd
Genomic Testing Cooperative
Guardant Health
HTG Molecular Diagnostics, Inc.
Illumina, Inc.
Invitae Corporation
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
NanoString
NeoGenomics Laboratories
Opko Health, Inc.
QIAGEN
Quest Diagnostics Incorporated.
Thermo Fisher Scientific, Inc.
VYANTbio.

1 Market

1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.1.2 Scope of Work
1.2 Market Overview
1.2.1 Solid Tumor Testing Workflow
1.3 Significant Technologies
1.4 Industry Participants Landscape
1.5 Epidemiology of Solid Tumors in the U.S.
1.5.1 Southern U.S.
1.5.2 Midwest U.S.
1.5.3 Mid-Atlantic U.S.
1.5.4 West U.S.
1.5.5 Southwest U.S.
1.5.6 New England
1.6 Future Potential

2 Industry Insights

2.1 Patent Analysis
2.1.1 Patent Filing Trend
2.1.1.1 Patent Analysis (by Year)
2.2 Legal Requirements
2.2.1 Regulation of Genetic Tests
2.2.1.1 The U.S. FDA Regulations
2.2.1.2 CMS Regulation
2.2.2 Reimbursement Scenario
2.2.2.1 Impact on Laboratory Analysis

3 Market Dynamics

3.1 Overview
3.1.1 Market Drivers
3.1.1.1 Rising Advancements in Solid Tumor Testing and Rapid Usage of Liquid Biopsy
3.1.1.2 Early Cancer Detection with Multi-Cancer Tests
3.1.1.3 Increasing Adoption of Inorganic Growth Strategies in the Market
3.1.1.4 Spike Increase in the Research Funding from National Cancer Institute
3.1.1.5 Rapid Adoption of Genetic Testing
3.1.2 Market Restraints
3.1.2.1 Reimbursement Cuts in the U.S.
3.1.2.2 High Pricing Pressure
3.1.3 Market Opportunities
3.1.3.1 Technological Innovation for Larger Consumer Base and Role of Informatics
3.1.3.2 Mushrooming Direct-to-Consumer (DTC) Testing Services Market
3.2 COVID-19 Impact on U.S. Solid Tumor Testing Market

4 Competitive Landscape

4.1 Competitive Landscape
4.1.1 Acquisitions
4.1.2 Synergistic Activities
4.1.3 Product Launches and Upgradations
4.1.4 Business Expansion
4.1.5 Fundings
4.1.6 Market Share Analysis (2020 and 2021)
4.1.7 Growth-Share Analysis (2021)
4.1.7.1 Growth-Share Analysis by Technology
4.1.7.2 Growth-Share Analysis by Biomarker Type
4.1.7.3 Growth-Share Analysis by Application
4.2 Supply Chain Analysis
4.3 Pricing Analysis (by Technology)

5 U.S. Solid Tumor Testing Market, by Technology, $Million, 2021 - 2032

5.1 Overview
5.1.1 Next-Generation Sequencing
5.1.2 Polymerase Chain Reaction
5.1.3 Fluorescence In-Situ Hybridization
5.1.4 Immunohistochemistry (IHC)
5.1.5 Liquid Chromatography/Mass Spectrometry
5.1.6 Other Technologies

6 U.S. Solid Tumor Testing Market, by Cancer Type, By Value ($Million), 2021-2032

6.1 Overview
6.1.1 Breast Cancer
6.1.2 Prostate Cancer
6.1.3 Colorectal Cancer
6.1.4 Lung Cancer
6.1.5 Melanoma
6.1.6 Endometrial Cancer
6.1.7 Lymphoma
6.1.8 Thyroid Cancer
6.1.9 Brain Cancer
6.1.10 Other Cancer Types

7 U.S. Solid Tumor Testing Market, by Type of Biomarker, By Value ($Million), 2021-2032

7.1 Overview
7.1.1 Genetic Biomarker
7.1.1.1 Molecular Biomarker
7.1.1.2 Cellular Biomarker
7.1.1.3 Imaging Biomarker
7.1.2 Protein Biomarker
7.1.2.1 Diagnostic Biomarker
7.1.2.2 Prognostic Biomarker
7.1.2.3 Predictive Biomarker
7.1.2.4 Predisposition Biomarker

8 U.S. Solid Tumor Testing Market, by Application, By Value ($Million), By Volume (Units), 2021-2032

8.1 Overview
8.1.1 Clinical
8.1.1.1 Diagnostics
8.1.1.2 Treatment and Monitoring
8.1.1.3 Screening
8.1.1.4 Prognosis
8.1.2 Research
8.1.2.1 Biomarker Discovery
8.1.2.2 Personalized Medicine

9 U.S. Solid Tumor Testing Market, by End-User, By Value ($Million), By Volume (Units), 2021-2032

9.1 Overview
9.1.1 Hospitals
9.1.2 Pharmaceutical and Biotechnology Companies
9.1.3 Contract Research Organizations
9.1.4 Academic Research Institutes
9.1.5 Other End Users

10 U.S. Solid Tumor Testing Market, by Region, $Million, 2021-2032

10.1 Overview
10.1.1 Southern U.S.
10.1.2 Midwest U.S.
10.1.3 Mid-Atlantic U.S.
10.1.4 West U.S.
10.1.5 Southwest U.S.
10.1.6 New England

11 Market - Competitive Benchmarking & Company Profiles

11.1 Overview
11.1.1 U.S. Solid Tumor Testing Value Chain
11.2 Abbott.
11.2.1 Company Overview
11.2.2 Role of Abbott. in the U.S. Solid Tumor Testing Market
11.2.3 Key Customers of the Company
11.2.4 Key Competitors of the Company
11.2.5 Financials
11.2.6 Key Insights about the Financial Health of the Company
11.2.7 Analyst Perspective
11.3 ARUP Laboratories.
11.3.1 Company Overview
11.3.2 Role of ARUP Laboratories. in the U.S. Solid Tumor Testing Market
11.3.3 Key Customers of the Company
11.3.4 Key Competitors of the Company
11.3.5 Corporate Strategies
11.3.6 Analyst Perspective
11.4 Bio-Rad Laboratories, Inc.
11.4.1 Company Overview
11.4.2 Role of Bio-Rad Laboratories, Inc. in the U.S. Solid Tumor Testing Market
11.4.3 Key Customers of the Company
11.4.4 Key Competitors of the Company
11.4.5 Financials
11.4.6 Key Insights about the Financial Health of the Company
11.4.7 Analyst Perspective
11.5 Caris Life Sciences.
11.5.1 Company Overview
11.5.2 Role of Caris Life Sciences. in the U.S. Solid Tumor Testing Market
11.5.3 Key Customers of the Company
11.5.4 Key Competitors of the Company
11.5.5 Corporate Strategies
11.5.6 Analyst Perspective
11.6 F. Hoffmann-La Roche Ltd
11.6.1 Company Overview
11.6.2 Role of F. Hoffmann-La Roche Ltd in the U.S. Solid Tumor Testing Market
11.6.3 Key Customers of the Company
11.6.4 Key Competitors of the Company
11.6.5 Business Strategies
11.6.6 Financials
11.6.7 Key Insights About Financial Health of the Company
11.6.8 Analyst Perspective
11.7 Genomic Testing Cooperative
11.7.1 Company Overview
11.7.2 Role of Genome Testing Cooperative in the U.S. Solid Tumor Testing Market
11.7.3 Key Competitors of the Company
11.7.4 Business Strategies
11.7.5 Analyst Perspective
11.8 Guardant Health
11.8.1 Company Overview
11.8.2 Role of Guardant Health in the U.S. Solid Tumor Testing Market
11.8.3 Key Competitors of the Company
11.8.4 Key Customers of the Company
11.8.5 Business Strategies
11.8.6 Corporate Strategies
11.8.7 Financials
11.8.8 Key Insights about the Financial Health of the Company
11.8.9 Analyst Perspective
11.9 HTG Molecular Diagnostics, Inc.
11.9.1 Company Overview
11.9.2 Role of HTG Molecular Diagnostics, Inc. in the U.S. Solid Tumor Testing Market
11.9.3 Key Competitors of the Company
11.9.4 Financials
11.9.5 Key Insights about the Financial Health of the Company
11.9.6 Analyst Perspective
11.1 Illumina, Inc.
11.10.1 Company Overview
11.10.2 Role of Illumina, Inc. in the U.S. Solid Tumor Testing Market
11.10.3 Key Competitors of the Company
11.10.4 Key Customers of the Company
11.10.5 Corporate Strategies
11.10.6 Financials
11.10.7 Key Insights about the Financial Health of the Company
11.10.8 1.1.7 Analyst Perspective
11.11 Invitae Corporation.
11.11.1 Company Overview
11.11.2 Role of Invitae Corporation. in the U.S. Solid Tumor Testing Market
11.11.3 Key Competitors of the Company
11.11.4 Key Customers of the Company
11.11.5 Corporate Strategies
11.11.6 Business Strategies
11.11.7 Financials
11.11.8 Key Insights about the Financial Health of the Company
11.11.9 Analyst Perspective
11.12 Invivoscribe, Inc.
11.12.1 Company Overview
11.12.2 Role of Invivoscribe, Inc. in the U.S. Solid Tumor Testing Market
11.12.3 Key Competitors of the Company
11.12.4 Analyst Perspective
11.13 Laboratory Corporation of America Holdings.
11.13.1 Company Overview
11.13.2 Role of Laboratory Corporation of America Holdings. in the U.S. Solid Tumor Testing Market
11.13.3 Key Competitors of the Company
11.13.4 Key Customers of the Company
11.13.5 Corporate Strategies
11.13.6 Business Strategies
11.13.7 Financials
11.13.8 Analyst Perspective
11.14 NanoString.
11.14.1 Company Overview
11.14.2 Role of NanoString. in the U.S. Solid Tumor Testing Market
11.14.3 Key Customers of the Company
11.14.4 Key Competitors of the Company
11.14.5 Corporate Strategies
11.14.6 Financials
11.14.7 Analyst Perspective
11.15 NeoGenomics Laboratories.
11.15.1 Company Overview
11.15.2 Role of NeoGenomics Laboratories. in the U.S. Solid Tumor Testing Market
11.15.3 Key Competitors of the Company
11.15.4 Corporate Strategies
11.15.5 Business Strategies
11.15.6 Financials
11.15.7 Key Insights about the Financial Health of the Company
11.15.8 Analyst Perspective
11.16 Opko Health, Inc.
11.16.1 Company Overview
11.16.2 Role of Opko Health, Inc. in the U.S. Solid Tumor Testing Market
11.16.3 Key Customers of the Company
11.16.4 Key Competitors of the Company
11.16.5 Business Strategies
11.16.6 Financials
11.16.7 Key Insights about the Financial Health of the
11.16.8 Analyst Perspective
11.17 QIAGEN
11.17.1 Company Overview
11.17.2 Role of QIAGEN in the U.S. Solid Tumor Testing Market
11.17.3 Key Customers of the Company
11.17.4 Key Competitors of the Company
11.17.5 Corporate Strategies
11.17.6 Business Strategies
11.17.7 Financials
11.17.8 Key Insights about the Financial Health of the
11.17.9 Analyst Perspective
11.18 Quest Diagnostics Incorporated.
11.18.1 Company Overview
11.18.2 Role of Quest Diagnostics Incorporated. in the U.S. Solid Tumor Testing Market
11.18.3 Key Customers of the Company
11.18.4 Key Competitors of the Company
11.18.5 Corporate Strategies
11.18.6 Business Strategies
11.18.7 Financials
11.18.8 Analyst Perspective
11.19 Thermo Fisher Scientific, Inc.
11.19.1 Company Overview
11.19.2 Role of Thermo Fisher Scientific, Inc. in the U.S. Solid Tumor Testing Market
11.19.3 Key Customers of the Company
11.19.4 Key Competitors of the Company
11.19.5 Business Strategies
11.19.6 Financials
11.19.7 Key Insights about the Financial Health of the Company
11.19.8 Analyst Perspective
11.2 VYANTbio.
11.20.1 Company Overview
11.20.2 Role of VYANTbio. in the U.S. Solid Tumor Testing Market
11.20.3 Key Competitors of the Company
11.20.4 Corporate Strategies
11.20.5 Financials
11.20.6 Analyst Perspective
11.21 Emerging Companies
11.21.1 OncXerna Therapeutics
11.21.2 PathAI
11.21.3 Century Therapeutics
11.21.4 Arcus Biosciences
11.21.5 OncoMed Pharmaceuticals
11.21.6 ALX Oncology

List of Figures

Figure 1: Impact Analysis of Market Drivers and Market Challenges on the U.S. Solid Tumor Testing Market
Figure 2: U.S. Solid Tumor Testing Market (by Technology), $Million, 2021 and 2032
Figure 3: U.S. Solid Tumor Testing Market (by Cancer Type), $Million, 2021 and 2032
Figure 4: U.S. Solid Tumor Testing Market (by Biomarker Type), $Million, 2021 and 2032
Figure 5: U.S. Solid Tumor Testing Market (by Application Type), $Million, 2021 and 2032
Figure 6: U.S. Solid Tumor Testing Market (by End User), $Million, 2021 and 2032
Figure 7: U.S. Solid Tumor Testing Market Research Methodology
Figure 8: U.S. Solid Tumor Testing Market: Segmentation
Figure 9: Solid Tumor Testing Workflow
Figure 10: Types of Solid Tumors
Figure 11: Estimated Percent of New Cancer Cases (by Sex), U.S., 2022
Figure 12: Expected Cancers Cases in the U.S. (by State), 2022
Figure 13: Relative Number of Expected Cancers Cases (by State), 2022
Figure 14: Relative Percent of Expected Cancers Cases (by Region), 2022
Figure 15: Estimated Number of New Cancer Cases by State in Southern U.S. (%), 2022
Figure 16: Estimated Number of New Cancer Cases by State in Midwest U.S. (%), 2022
Figure 17: Estimated Number of New Cancer Cases by State in Mid-Atlantic U.S. (%), 2022
Figure 18: Estimated Number of New Cancer Cases by State in West U.S., (%), 2022
Figure 19: Estimated Number of New Cancer Cases by State in Southwest U.S. (%), 2022
Figure 20: Estimated Number of New Cancer Cases by State in New England (%) 2022
Figure 21: Year-Wise Analysis of Patents Related to Solid Tumor Testing, January 2019-May 2022
Figure 22: Reimbursement Components in the U.S.
Figure 23: U.S. Solid Tumor Testing Market - Market Dynamics
Figure 24: Tissue Biopsy vs. Liquid Biopsy
Figure 25: Synergistic Activities, 2019-2021
Figure 26: SBIR and STTR Grants and Contract Funding, 2008-2018
Figure 27: NCI Fiscal Budget Year on Year, 2013-2018
Figure 28: Reimbursement Cuts Adopted for Oncology Testing, as per PAMA Revisions
Figure 29: National Expenditures for Medical Services Related to Cancer Care Estimates by Cancer Site and Year (Billions of Dollars)
Figure 30: Key Players Offering
Figure 31: COVID-19 Impact
Figure 32: Share of Key Developments and Strategies, January 2019-April 2022
Figure 33: Share of Acquisitions (by Company), January 2019-April 2022
Figure 34: Synergistic Activities Share (by Company), January 2019-April 2022
Figure 35: Product Launches and Upgradations (by Company), January 2019-April 2022
Figure 36: Share of Business Expansion Activities (by Company), January 2019-April 2022
Figure 37: Share of Funding Activities (by Company), January 2019-April 2022
Figure 38: Market Share Analysis for U.S. Solid Tumor Testing Market, (by Services), $Million, 2020 and 2021
Figure 39: Growth-Share Analysis of the U.S. Solid Tumor Testing Market (by Technology), 2021
Figure 40: Growth-Share Matrix for U.S. Solid Tumor Testing Market (by Biomarker Type), 2021
Figure 41: Growth-Share Matrix for U.S. Solid Tumor Testing Market (by Application), 2021
Figure 42: Supply Chain Analysis of the U.S. Solid Tumor Testing Market
Figure 43: U.S. Solid Tumor Testing Market (by Technology)
Figure 44: Share of U.S. Solid Tumor Testing Market (by Technology), $Million, 2020 and 2031
Figure 45: U.S. Solid Tumor Testing Market, 000’ Units, 2021-2032
Figure 46: U.S. Solid Tumor Testing Market (Next-Generation Sequencing), 2021-2032
Figure 47: U.S. Solid Tumor Testing Market (Next-Generation Sequencing), 000’ Units, 2021-2032
Figure 48: U.S. Solid Tumor Testing Market (Polymerase Chain Reaction), $Million, 2021-2032
Figure 49: U.S. Solid Tumor Testing Market (Polymerase Chain Reaction), 000’ Units, 2021-2032
Figure 50: U.S. Solid Tumor Testing Market (Fluorescence In-Situ Hybridization), $Million, 2021-2032
Figure 51: U.S. Solid Tumor Testing Market (Fluorescence In-Situ Hybridization), 000’ Units, 2021-2032
Figure 52: U.S. Solid Tumor Testing Market (Immunohistochemistry), 2021-2032
Figure 53: U.S. Solid Tumor Testing Market (Immunohistochemistry), 000’ Units, 2021-2032
Figure 54: U.S. Solid Tumor Testing Market (Liquid Chromatography/Mass Spectrometry), 2021-2032
Figure 55: U.S. Solid Tumor Testing Market (Liquid Chromatography/Mass Spectrometry), 000’ Units, 2021-2032
Figure 56: U.S. Solid Tumor Testing Market (Other Technologies), 2021-2032
Figure 57: U.S. Solid Tumor Testing Market (Other Technologies), 000’ Units, 2021-2032
Figure 58: U.S. Solid Tumor Testing Market (by Cancer Types)
Figure 59: Share of U.S. Solid Tumor Testing Market (by Cancer Type), $Million, 2021 and 2032
Figure 60: National Cancer Care Expenditure Estimates (by Cancer Site and Year), $Billion
Figure 61: Net Patient Economic Burden Associated with Cancer in the U.S. in 2019 (in Millions)
Figure 62: U.S. Solid Tumor Testing Market (by Cancer Type), 2021-2032
Figure 63: Estimated New Cancer Cases and Deaths for Breast Cancer, 2022
Figure 64: U.S. Solid Tumor Testing Market (Breast Cancer), $Million, 2021-2032
Figure 65: Estimated New Cancer Cases and Deaths for Prostate Cancer, 2022
Figure 66: U.S. Solid Tumor Testing Market (Prostate Cancer), $Million, 2021-2032
Figure 67: Estimated New Cancer Cases and Deaths for Colorectal Cancer, 2022
Figure 68: U.S. Solid Tumor Testing Market (Colorectal Cancer), $Million, 2021-2032
Figure 69: Estimated New Cancer Cases and Deaths for Lung and Bronchus Cancer, 2022
Figure 70: U.S. Solid Tumor Testing Market (Lung Cancer), $Million, 2021-2032
Figure 71: Estimated New Cancer Cases and Deaths for Melanoma of the Skin, 2022
Figure 72: U.S. Solid Tumor Testing Market (Melanoma), $Million, 2021-2032
Figure 73: Estimated New Cancer Cases and Deaths for Endometrial Cancer (Uterine Cancer), 2022
Figure 74: U.S. Solid Tumor Testing Market (Endometrial Cancer), $Million, 2021-2032
Figure 75: Estimated New Cancer Cases and Deaths for Non-Hodgkin's Lymphoma, 2022
Figure 76: U.S. Solid Tumor Testing Market (Lymphoma), $Million, 2021-2032
Figure 77: Estimated New Cancer Cases and Deaths for Thyroid Cancer, 2022
Figure 78: U.S. Solid Tumor Testing Market (Thyroid Cancer), $Million, 2021-2032
Figure 79: Estimated New Cancer Cases and Deaths for Brain and Other Nervous System Cancer, 2022
Figure 80: U.S. Solid Tumor Testing Market (Brain Cancer), $Million, 2021-2032
Figure 81: U.S. Solid Tumor Testing Market (Other Cancer Types), $Million, 2021-2032
Figure 82: U.S. Solid Tumor Testing Market (by Type of Biomarker)
Figure 83: Share of U.S. Solid Tumor Testing Market (by Type of Biomarker), $Million, 2021 and 2032
Figure 84: Technologies and Data Types for Genetic Biomarker Discovery
Figure 85: U.S. Solid Tumor Testing Market (Genetic Biomarker), $Million, 2021-2032
Figure 86: U.S. Solid Tumor Testing Market (by Genetic Biomarker), $Million, 2021 and 2032
Figure 87: U.S. Solid Tumor Testing Market (Molecular Biomarker), $Million, 2021-2032
Figure 88: U.S. Solid Tumor Testing Market (Cellular Biomarker), $Million, 2021-2032
Figure 89: U.S. Solid Tumor Testing Market (Imaging Biomarker), $Million, 2021-2032
Figure 90: Development of Imaging Biomarkers
Figure 91: Technologies and Data Types for Protein Biomarker Discovery
Figure 92: U.S. Solid Tumor Testing Market (Protein Biomarker), $Million, 2021-2032
Figure 93: U.S. Solid Tumor Testing Market (by Protein Biomarker), $Million, 2021 and 2032
Figure 94: U.S. Solid Tumor Testing Market (Diagnostic Biomarker), $Million, 2021-2032
Figure 95: U.S. Solid Tumor Testing Market (Prognostic Biomarker), $Million, 2021-2032
Figure 96: U.S. Solid Tumor Testing Market (Predictive Biomarker), $Million, 2021-2032
Figure 97: U.S. Solid Tumor Testing Market (Predisposition Biomarker), $Million, 2021-2032
Figure 98: U.S. Solid Tumor Testing Market (by Application)
Figure 99: U.S. Solid Tumor Testing Market (by Application), $Million, 2021 and 2032
Figure 100: U.S. Solid Tumor Testing Market (Clinical), $Million, 2021-2032
Figure 101: U.S. Solid Tumor Testing Market (Clinical), $Million, 2021 and 2032
Figure 102: U.S. Solid Tumor Testing Market (Clinical), 000’ Units, 2021-2032
Figure 103: U.S. Solid Tumor Testing Market (Diagnostics), $Million, 2021-2032
Figure 104: U.S. Solid Tumor Testing Market (Treatment and Monitoring), $Million, 2021-2032
Figure 105: U.S. Solid Tumor Testing Market (Screening), $Million, 2021-2032
Figure 106: U.S. Solid Tumor Testing Market (Prognosis), $Million, 2021-2032
Figure 107: U.S. Solid Tumor Testing Market (Research), $Million, 2021-2032
Figure 108: U.S. Solid Tumor Testing Market (by Research), $Million, 2021 and 2032
Figure 109: U.S. Solid Tumor Testing Market (Research), 000’ Units, 2021-2032
Figure 110: U.S. Solid Tumor Testing Market (Biomarker Discovery), $Million, 2021-2032
Figure 111: U.S. Solid Tumor Testing Market (Personalized Medicine), $Million, 2021-2032
Figure 112: U.S. Solid Tumor Testing Market (by End User)
Figure 113: Share of U.S. Solid Tumor Testing Market (by End User), $Million, 2021 and 2032
Figure 114: U.S. Solid Tumor Testing Market (Hospitals), $Million, 2021-2032
Figure 115: U.S. U.S. Solid Tumor Testing Market (Hospitals), 000’ Units, 2021-2032
Figure 116: U.S. Solid Tumor Testing Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2032
Figure 117: U.S. Solid Tumor Testing Market (Pharmaceutical and Biotechnology Companies), 000’ Units, 2021-2032
Figure 118: U.S. Solid Tumor Testing Market (Contract Research Organizations), $Million, 2021-2032
Figure 119: U.S. Solid Tumor Testing Market (Contract Research Organizations), 000’ Units, 2021-2032
Figure 120: U.S. Solid Tumor Testing Market (Academic Research Institutes), $Million, 2021-2032
Figure 121: U.S. Solid Tumor Testing Market (Academic Research Institutes), 000’ Units, 2021-2032
Figure 122: U.S. Solid Tumor Testing Market (Other End Users), $Million, 2021-2032
Figure 123: U.S. Solid Tumor Testing Market (Other End Users), 000’ Units, 2021-2032
Figure 124: U.S. Solid Tumor Testing Market (Region), $Million, 2021-2032
Figure 125: Cancer Mortality by State in 2020
Figure 126: Southern U.S. Solid Tumor Testing Market, $Million, 2021-2032
Figure 127: Midwest U.S. Solid Tumor Testing Market, $Million, 2021-2032
Figure 128: Mid-Atlantic U.S. Solid Tumor Testing Market, $Million, 2021-2032
Figure 129: West U.S. Solid Tumor Testing Market, $Million, 2021-2032
Figure 130: Southwest U.S. Solid Tumor Testing Market, $Million, 2021-2031
Figure 131: New England Solid Tumor Testing Market, $Million, 2021-2032
Figure 132: U.S. Solid Tumor Testing Market (Other Technologies), 2021-2032
Figure 133: U.S. Solid Tumor Testing Market (Other Technologies), Units, 2021-2032
Figure 134: Total Number of Companies Profiled
Figure 135: U.S. Solid Tumor Testing Market Value Chain
Figure 136: Abbott.: Overall Product Portfolio
Figure 137: Abbott.: Overall Financials, 2019-2021
Figure 138: Abbott.: Revenue (by Segment), 2019-2021
Figure 139: Abbott.: Revenue (by Region), 2019-2021
Figure 140: Abbott.: R&D Expenditure, 2019-2021
Figure 141: ARUP Laboratories.: Overall Product Portfolio
Figure 142: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 143: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 144: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 145: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 146: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 147: Caris Life Sciences.: Overall Product Portfolio
Figure 148: F. Hoffmann-La Roche Ltd: Portfolio
Figure 149: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
Figure 150: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 151: F. Hoffmann-La Roche Ltd: Sales (by Region), 2019-2021
Figure 152: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 153: Genomic Testing Cooperative: Overall Product Portfolio
Figure 154: Guardant Health: Overall Product Portfolio
Figure 155: Guardant Health: Overall Financials, 2019-2021
Figure 156: Guardant Health: Revenue (by Segment), 2019-2021
Figure 157: Guardant Health: R&D Expenditure, 2019-2021
Figure 158: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
Figure 159: HTG Molecular Diagnostics, Inc.: Overall Financials, 2018-2020
Figure 160: HTG Molecular Diagnostics, Inc.: Revenue (by Segment), 2018-2020
Figure 161: HTG Molecular Diagnostics, Inc.: R&D Expenditure, 2018-2020
Figure 162: Illumina, Inc.: Overall Product Portfolio
Figure 163: Illumina, Inc.: Overall Financials, 2019-2021
Figure 164: Illumina, Inc.: Revenue (by Segment), 2019-2021
Figure 165: Illumina, Inc.: Revenue (by Region), 2019-2021
Figure 166: Illumina, Inc.: R&D Expenditure, 2019-2021
Figure 167: Invitae Corporation.: Overall Product Portfolio
Figure 168: Invitae Corporation.: Overall Financials, 2018-2020
Figure 169: Invitae Corporation.: Revenue (by Segment), 2018-2020
Figure 170: Invitae Corporation.: Revenue (by Region), 2019-2021
Figure 171: Invitae Corporation.: R&D Expenditure, 2019-2021
Figure 172: Invivoscribe, Inc.: Product Portfolio
Figure 173: Laboratory Corporation of America Holdings.: Overall Product Portfolio
Figure 174: Laboratory Corporation of America Holdings.: Overall Financials, 2019-2021
Figure 175: Laboratory Corporation of America Holdings.: Revenue (by Segment), 2019-2021
Figure 176: Laboratory Corporation of America Holdings.: Revenue (by Region), 2019-2021
Figure 177: NanoString.: Overall Product Portfolio
Figure 178: NanoString.: Overall Financials, $Million, 2019-2021
Figure 179: NanoString.: Revenue (by Segment), 2019-2021
Figure 180: NanoString.: Revenue (by Region), $Million, 2019-2021
Figure 181: NeoGenomics Laboratories.: Overall Product Portfolio
Figure 182: NeoGenomics Laboratories.: Overall Financials, $Million, 2019-2021
Figure 183: NeoGenomics Laboratories.: Revenue (by Segment), $Million, 2019-2021
Figure 184: NeoGenomics Laboratories.: R&D Expenditure, 2019-2021
Figure 185: Opko Health, Inc.: Overall Product Portfolio
Figure 186: Opko Health, Inc.: Overall Financials, $Million, 2019-2021
Figure 187: Opko Health, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 188: Opko Health, Inc.: R&D Expenditure, 2019-2021
Figure 189: QIAGEN: Overall Product Portfolio
Figure 190: QIAGEN: Overall Financials, $Million, 2019-2021
Figure 191: QIAGEN: Revenue (by Segment), $Million, 2019-2021
Figure 192: QIAGEN: Revenue (by Region), $Million, 2019-2021
Figure 193: QIAGEN: R&D Expenditure, 2019-2021
Figure 194: Quest Diagnostics Incorporated.: Overall Product Portfolio
Figure 195: Quest Diagnostics Incorporated.: Overall Financials, $Million, 2019-2021
Figure 196: Quest Diagnostics Incorporated.: Revenue (by Segment), $Million, 2019-2021
Figure 197: Thermo Fisher Scientific, Inc.: Overall Product Portfolio
Figure 198: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2019-2021
Figure 199: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 200: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 201: Thermo Fisher Scientific, Inc.: R&D Expenditure, 2019-2021
Figure 202: VYANTbio.: Overall Financials, $Million, 2019-2021

List of Tables

Table 1: Solid Tumor Testing Technologies for Clinical Laboratories
Table 2: Technological Trends in Solid Tumor Testing Market
Table 3: Industry Participants' Landscape in the U.S Solid Tumor Testing Market
Table 4: New Payment Amounts for ADLTs
Table 5: FDA-Approved Stratification Biomarkers for Targeted Therapies in Oncology
Table 6: Some FDA-Approved Diagnostic Biomarkers
Table 7: Some Prognostic Biomarkers
Table 8: Estimated Cancer Deaths in California, 2022
Table 9: Estimated Cancer Deaths in Texas, 2022

Executive Summary

The premium market intelligence report published under the title U.S. Solid Tumor Testing Market highlights that the market is projected to reach $18,287.6 million by 2032. The study also highlights that the market is set to witness a CAGR of 6.19% during the forecast period 2022-2032.

Solid tumors may be benign (not cancerous) or malignant (cancerous). In the current study, considerations for solid tumors follow the definition of the National Cancer Institute. Examples include sarcomas, carcinomas, and lymphomas of the organs that are affected. Major solid tumors include breast cancer, prostate cancer, colorectal cancer, lung cancer, and melanoma, among others. The market is expected to grow at a significant growth rate due to the opportunities such as the introduction of informatics and technological innovations for a large customer base and increasing adoption of genetic testing services.

The comprehensive study covers the following:

Market numbers on micro-segments that are influencing the market
Market share analysis for more than 20 companies
Study of data of more than 30 companies
Application analysis of the U.S. solid tumor testing market in various states of the U.S.

Who should buy this report?

Solid tumor testing products and services manufacturers who are planning to invest in one of the large established markets
Companies involved in the ecosystem of U.S. solid tumor testing
Companies in the U.S. solid tumor testing market
Companies involved in developing treatment regimens for cancer and its various types.

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include technology, biomarker type, cancer type, application, end user, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

The premium market intelligence also highlights the opportunities existing in the market, including the solid tumor testing services in the U.S. The study is majorly centered on the sub-segments and micro-segments of the different solid tumor testing products in the market.

To emphasize the dominance of the Southwest U.S. segment in the U.S. solid tumor testing market in 2021 and 2032, Nitish Kumar Singh, Principal Analyst at the publisher states, "The Southwest U.S. is the leading contributor to the U.S. solid tumor testing market. It contributed approximately 27.53% to the market value in 2021. This state is anticipated to grow at a CAGR of 6.62% during the forecast period 2022-2032 and will continue dominating the global market in 2032. However, the West U.S. is expected to grow at an impressive CAGR of 8.00% during the forecast period 2022- 2032.”

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players profiled in the report include F. Hoffmann La Roche Ltd, Abbott., Illumina, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., QIAGEN, Guardant Health, NeoGenomics Laboratories, Laboratory Corporation of America Holdings., and other companies.

The study also offers strategic recommendations that can help organizations track various products, trends, and applications that are changing the dynamics of the market. The recommendations by the publisher also offer bespoke research services to help organizations meet their objectives.

Insightful Questions Covered to Enable Companies to take Strategic Decisions

How is U.S. solid tumor testing market revolutionizing the field of oncology?
What are the major market drivers, challenges, and opportunities in the U.S. solid tumor testing market?
What are the underlying structures resulting in the emerging trends within the U.S. solid tumor testing market?
How did the COVID-19 pandemic impact the U.S. solid tumor testing market ecosystem?
What are the key development strategies that are being implemented by major players in order to sustain themselves in the competitive market?
What are the key regulatory implications in developed and developing regions pertaining to the use of solid tumor testing services?
What are the potential entry barriers that are expected to be faced by companies willing to enter a particular state of the U.S.?
What are the growth opportunities for companies in the region of their operation?
Who are the leading players with significant offerings in the U.S. solid tumor testing market?
Which companies are anticipated to be highly disruptive in the future and why?

Companies Mentioned

Abbott.
ARUP Laboratories
Bio-Rad Laboratories, Inc.
Caris Life Sciences.
F. Hoffmann-La Roche Ltd
Genomic Testing Cooperative
Guardant Health
HTG Molecular Diagnostics, Inc.
Illumina, Inc.
Invitae Corporation
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
NanoString
NeoGenomics Laboratories
Opko Health, Inc.
QIAGEN
Quest Diagnostics Incorporated.
Thermo Fisher Scientific, Inc.
VYANTbio.

Table Information

Report Attribute	Details
No. of Pages	283
Published	June 2022
Forecast Period	2022 - 2032
Estimated Market Value ( USD ) in 2022	$ 10025.9 Million
Forecasted Market Value ( USD ) by 2032	$ 18287.6 Million
Compound Annual Growth Rate	6.2%
Regions Covered	United States
No. of Companies Mentioned	19

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€5153EUR$5,250USD£4,308GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€7950EUR$8,100USD£6,646GBP